Profile data is unavailable for this security.
About the company
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
- Revenue in INR (TTM)168.27bn
- Net income in INR6.04bn
- Incorporated1978
- Employees3.44k
- LocationBiocon Ltd20th KM, Hosur Road, Electronic City,BANGALORE 560100IndiaIND
- Phone+91 8 028082808
- Fax+91 8 028523423
- Websitehttps://www.biocon.com/
Mergers & acquisitions
| Acquired company | BIOCON:NSI since announced | Transaction value |
|---|---|---|
| Biocon Biologics Ltd | 12.89% | 1.15bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Allist Pharmaceuticals Co Ltd | 63.36bn | 26.41bn | 578.02bn | 1.42k | 21.89 | 6.68 | -- | 9.12 | 4.41 | 4.41 | 10.57 | 14.44 | 0.7497 | 5.75 | 13.98 | 3,357,423.00 | 31.24 | 10.89 | 34.76 | 11.75 | 95.37 | 96.19 | 41.68 | 27.72 | 5.34 | -- | 0.0006 | 24.71 | 76.29 | 462.87 | 121.97 | -- | 24.77 | -- |
| Shanghai Bao Pharmaceuticals Co Ltd | 620.81m | -5.06bn | 612.23bn | -- | -- | 51.73 | -- | 986.18 | -1.32 | -1.32 | 0.1622 | 3.09 | -- | -- | -- | -- | -- | -- | -- | -- | 97.96 | -- | -814.93 | -- | 2.07 | -- | 0.2168 | -- | -11.11 | -- | -127.21 | -- | -- | -- |
| Biocon Ltd | 168.27bn | 6.04bn | 626.36bn | 3.44k | 79.75 | -- | 24.96 | 3.72 | 4.85 | 4.85 | 133.23 | -- | -- | -- | -- | 48,888,440.00 | -- | 2.72 | -- | 3.92 | 65.74 | 62.04 | 3.74 | 8.83 | -- | 1.66 | -- | 9.26 | 3.43 | 19.36 | -0.8998 | 5.45 | 4.99 | -- |
| RemeGen Co Ltd | 29.67bn | -12.62bn | 629.31bn | 3.00k | -- | 22.59 | -- | 21.21 | -1.75 | -1.75 | 4.10 | 4.12 | 0.3812 | 0.541 | 6.40 | 742,854.40 | -16.21 | -19.20 | -27.09 | -23.96 | 82.97 | 81.06 | -42.54 | -87.98 | 0.7278 | -9.93 | 0.4848 | -- | 58.54 | 223.78 | 2.84 | -- | 32.40 | -- |
| PharmaEssentia Corp | 44.99bn | 14.52bn | 752.60bn | 131.00 | 50.64 | 8.00 | 48.05 | 16.73 | 13.61 | 13.61 | 42.17 | 86.15 | 0.4567 | 1.31 | 4.41 | -- | 14.74 | 3.17 | 16.48 | 3.58 | 89.23 | 86.29 | 32.27 | 9.45 | 5.93 | -- | 0.0261 | 28.70 | 60.61 | 94.81 | 70.13 | -- | 57.56 | -- |
| Holder | Shares | % Held |
|---|---|---|
| SBI Funds Management Ltd.as of 16 Jan 2026 | 114.08m | 7.04% |
| Life Insurance Corporation of India (Investment Portfolio)as of 19 Jun 2025 | 60.31m | 3.72% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 41.85m | 2.58% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Jan 2026 | 26.29m | 1.62% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 22.86m | 1.41% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Jan 2026 | 20.55m | 1.27% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Jan 2026 | 18.53m | 1.14% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Jan 2026 | 11.48m | 0.71% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Jan 2026 | 10.45m | 0.65% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 8.05m | 0.50% |
